A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Director, Epidemiology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$207.1k - $280.1kIn-person

About the Job

Requirements

  • A PhD in Epidemiology or another quantitative public health discipline is required.
  • Experience applying epidemiologic methods in at least one disease area is required; pharmacoepidemiologic techniques are preferred.
  • At least five years of experience in the pharmaceutical industry or equivalent experience in an academic or government setting is required.
  • Current knowledge of emerging guidance from regulatory authorities on designing observational studies and using real-world data to support decision-making is required.
  • Current knowledge and expertise in emerging analytical methodologies, tools, and applications to ensure fit-for-purpose and innovative approaches to using real-world data to address relevant questions is required.
  • The ability to deliver complex epidemiological studies in a regulated environment with moderate supervision is required.
  • The ability to communicate effectively at both lay and technical levels to inform stakeholders about the utility of real-world evidence across the product lifecycle and encourage use of study and analysis results in internal and external decisions is required.
  • The ability to work successfully in a matrixed environment with multiple stakeholders is required.
  • The ability to manage priorities, resources, and performance targets is required.
  • Knowledge of private and public-use datasets for epidemiological studies is required.
  • Basic knowledge of regulatory requirements in the pharmaceutical industry is required.
  • Proficient written and communication skills are required.

Responsibilities

  • Assess disease-target incidence and prevalence rigorously using literature reviews, database analysis, or extrapolation of estimates.
  • Guide and advise clinical development study teams on designing and collecting natural history data to understand disease progression, including risk factors and optimal endpoints for clinical trials.
  • Use real-world and clinical data to refine the size and characteristics of disease-target populations as clinical development progresses in rare and prevalent disease areas.
  • Partner with Clinical Research and Global Patient Safety and Risk Management to interpret and refine potential safety signals during drug development.
  • Partner with biostatisticians and statistical programming teams to implement and provide technical oversight of analyses from natural history and other observational studies, supporting clinical development and preparing scientific publications, presentations, and abstracts.
  • Provide strategic and tactical expertise on developing real-world evidence for external comparators, including advising on appropriate methodologies for regulatory use of real-world evidence.
  • Support regulatory submissions by authoring epidemiology sections of orphan or breakthrough designation applications and dossiers, and provide scientific leadership on the design of post-marketing commitment studies.
  • Partner with Global Patient Safety and Risk Management to deliver and oversee Risk Evaluation and Mitigation Strategies, risk management plans, and post-approval safety studies.
  • Author epidemiology sections of Development Safety Update Reports and Periodic Benefit-Risk Evaluation Reports.
  • Investigate and understand potential safety signals for marketed RNA interference therapeutics.
  • Establish real-world data partnerships with Medical Affairs and Commercial and coordinate data acquisition to avoid duplication.
  • Provide leadership in developing innovative real-world evidence approaches, techniques, and standards across teams.
  • Mentor junior epidemiologists and real-world evidence and observational analysts to support their epidemiologic skills and knowledge.

Desired Qualifications

  • Ophthalmology experience is highly preferred.
  • Experience applying pharmacoepidemiologic techniques is preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs